Most Read

The approval covers all existing indications for Rybrevant. The SC formulation reduces administration time from several hours to five minutes, compared to intravenous (IV) delivery, offering increased patient

FL is the most common slow-growing B-cell non-Hodgkin lymphoma form. Minjuvi is a humanised, fragment crystallisable-modified cytolytic monoclonal antibody targeting cluster of differentiation 19. The EC approval follows

This is claimed to become the first fully dedicated small-interfering RNA (siRNA) enzymatic-ligation manufacturing facility. The facility expansion is intended to increase capacity, lower production expenses, and enable

Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of the antibodies. Harbour BioMed, in exchange, is eligible to obtain payments

The company’s plans are expected to increase the capacity for injectable drug products. The expansion, scheduled to commence in early 2026, will add around 300,000ft² of purpose-built space

The expansion is targeted at individuals for whom topical corticosteroids are not sufficient or appropriate. The European regulator has accepted the application for review. The submission is based

The investment values Swixx at more than €1.5bn ($1.76bn). Swixx operates as a commercialisation platform for pharma companies, focusing on markets where those companies have chosen not to

Rett syndrome is a rare neurodevelopmental disorder that progresses through four stages. The formulation is intended to treat the condition in adult and paediatric patients aged two years

Sobi will purchase for Arthrosi Skr9.1bn ($950m) in cash. Additional payments of up to Skr5.3bn ($550m) may be made based on clinical, regulatory and sales milestones. The acquisition